What's Going On With NLS Pharmaceutics Shares Monday?
What's Going On With NLS Pharmaceutics Shares Monday?
"We are pleased to announce our merger with NLS and believe that the exposure of the combined company's assets to the U.S. capital markets through our new Nasdaq listing will enable us to develop our portfolio and increase Kadimastem shareholder value," said Kadimastem's executive chairman and president NLS Pharmaceutics Ltd. (NASDAQ:NLSP) shares are moving higher on Monday after the company announced it entered into a definitive merger agreement with Kadimastem.
NLS製藥有限公司（納斯達克：NLSP）股價週一上漲，因公司宣佈與Kadimastem達成了明確的合併協議。
What To Know: The combined company aims to advance NLS's Dual Orexin Agonist (DOXA) platform and Kadimastem's allogenic cell therapy program, which focuses on treatment candidates primarily targeting diabetes and amyotrophic lateral sclerosis (ALS).
需要了解的是：合併後的公司旨在推進NLS的雙促睡覺素拮抗劑（DOXA）平台和Kadimastem的異基因細胞療法項目，重點是治療主要針對糖尿病和肌萎縮側索硬化症（ALS）的候選藥物。
As a part of the merger, NLS will issue shares of its common stock to Kadimastem's shareholders, with an initial target distribution of 85% to Kadimastem shareholders and 15% to NLS shareholders in exchange for all of Kadimastem's shares. The share distribution may be adjusted according to the terms of the merger agreement.
作爲合併的一部分，NLS將向Kadimastem的股東發行其普通股，最初的目標分配爲85%給Kadimastem股東，15%給NLS股東，以換取Kadimastem所有股份。根據合併協議的條款，股份分配可能會進行調整。
"We are pleased to announce our merger with NLS and believe that the exposure of the combined company's assets to the U.S. capital markets through our new Nasdaq listing will enable us to develop our portfolio and increase Kadimastem shareholder value," said Kadimastem's executive chairman and president Ronen Twito.
Kadimastem的執行主席兼總裁羅南·特維託表示：「我們很高興宣佈與NLS的合併，並相信通過我們的新納斯達克上市，使合併公司的資產暴露於美國資本市場，將使我們能夠發展我們的投資組合並增加Kadimastem的股東價值。」
"We remain focused on initiating our Phase IIa multi-site clinical trial of AstroRx, a product candidate for the potential treatment of ALS, which is planned to be initiated following the closing of the merger, and jointly progressing our diabetes program IsletRx with our U.S. based partner to a pre-investigational new drug (IND) submission with the U.S. Food and Drug Administration in the first quarter of 2025."
「我們將繼續專注於啓動我們的AstroRx第IIa期多中心臨床試驗，這是一個潛在用於治療ALS的產品候選藥物，計劃在合併結束後啓動，並與我們的美國合作伙伴共同推進我們的糖尿病項目IsletRx，將其推進至到2025年第一季度向美國食品和藥物管理局提交預臨床階段（IND）申請。」
The merger is expected to close in Jan. 2025, pending approval of shareholders from both companies along with Nasdaq approval.
預計合併將於2025年1月結束，前提是得到兩家公司股東的批准以及納斯達克的批准。
NLSP Price Action: At the time of writing, NLS Pharmaceutics stock is moving 9.72% higher at $3.95, according to data from Benzinga Pro.
NLSP股價走勢：截至撰寫本文之時，NLS製藥股票以3.95美元的價格上漲了9.72％，數據來自Benzinga Pro。
Image: Photo by roberto-sorin for Unsplash
圖片：由roberto-sorin提供的Unsplash
譯文內容由第三人軟體翻譯。
